Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD.
CGRP monoclonal antibodies
Migraine
gepants
headache
pain
trigeminovascular
Journal
Cephalalgia : an international journal of headache
ISSN: 1468-2982
Titre abrégé: Cephalalgia
Pays: England
ID NLM: 8200710
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
pubmed:
26
3
2022
medline:
27
7
2022
entrez:
25
3
2022
Statut:
ppublish
Résumé
This study investigated the mechanism of action of atogepant, a small-molecule CGRP receptor antagonist recently approved for the preventive treatment of episodic migraine, by assessing its effect on activation of mechanosensitive C- and Aδ-meningeal nociceptors following cortical spreading depression. Single-unit recordings of trigeminal ganglion neurons (32 Aδ and 20 C-fibers) innervating the dura was used to document effects of orally administered atogepant (5 mg/kg) or vehicle on cortical spreading depression-induced activation in anesthetized male rats. Bayesian analysis of time effects found that atogepant did not completely prevent the activation of nociceptors at the tested dose, but it significantly reduced response amplitude and probability of response in both the C- and the Aδ-fibers at different time intervals following cortical spreading depression induction. For C-fibers, the reduction in responses was significant in the early phase (first hour), but not delayed phase of activation, whereas in Aδ-fibers, significant reduction in activation was apparent in the delayed phase (second and third hours) but not early phase of activation. These findings identify differences between the actions of atogepant, a small molecule CGRP antagonist (partially inhibiting both Aδ and C-fibers) and those found previously for fremanezumab, a CGRP-targeted antibody (inhibiting Aδ fibers only) and onabotulinumtoxinA (inhibiting C-fibers only)- suggesting that these agents differ in their mechanisms for the preventive treatment of migraine.
Sections du résumé
BACKGROUND
This study investigated the mechanism of action of atogepant, a small-molecule CGRP receptor antagonist recently approved for the preventive treatment of episodic migraine, by assessing its effect on activation of mechanosensitive C- and Aδ-meningeal nociceptors following cortical spreading depression.
METHODS
Single-unit recordings of trigeminal ganglion neurons (32 Aδ and 20 C-fibers) innervating the dura was used to document effects of orally administered atogepant (5 mg/kg) or vehicle on cortical spreading depression-induced activation in anesthetized male rats.
RESULTS
Bayesian analysis of time effects found that atogepant did not completely prevent the activation of nociceptors at the tested dose, but it significantly reduced response amplitude and probability of response in both the C- and the Aδ-fibers at different time intervals following cortical spreading depression induction. For C-fibers, the reduction in responses was significant in the early phase (first hour), but not delayed phase of activation, whereas in Aδ-fibers, significant reduction in activation was apparent in the delayed phase (second and third hours) but not early phase of activation.
CONCLUSIONS
These findings identify differences between the actions of atogepant, a small molecule CGRP antagonist (partially inhibiting both Aδ and C-fibers) and those found previously for fremanezumab, a CGRP-targeted antibody (inhibiting Aδ fibers only) and onabotulinumtoxinA (inhibiting C-fibers only)- suggesting that these agents differ in their mechanisms for the preventive treatment of migraine.
Identifiants
pubmed: 35332801
doi: 10.1177/03331024221083544
pmc: PMC9329220
mid: NIHMS1808569
doi:
Substances chimiques
Piperidines
0
Pyridines
0
Pyrroles
0
Spiro Compounds
0
atogepant
7CRV8RR151
Calcitonin Gene-Related Peptide
JHB2QIZ69Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
933-943Subventions
Organisme : NINDS NIH HHS
ID : R01 NS069847
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS094198
Pays : United States
Organisme : NINDS NIH HHS
ID : R37 NS079678
Pays : United States
Références
Cephalalgia. 2020 Dec;40(14):1585-1604
pubmed: 32811179
J Neurophysiol. 1993 Jun;69(6):2116-28
pubmed: 8350135
Physiol Rev. 1984 Jan;64(1):260-324
pubmed: 6320234
Pain. 2021 Oct 1;162(10):2499-2511
pubmed: 34108435
J Neurophysiol. 1989 Oct;62(4):907-16
pubmed: 2809709
Rev Neurol (Paris). 2005 Jul;161(6-7):655-7
pubmed: 16141950
J Headache Pain. 2020 Oct 6;21(1):120
pubmed: 33023473
Cephalalgia. 2018 Feb;38(2):246-258
pubmed: 27899434
Sci Rep. 2018 Jan 30;8(1):1836
pubmed: 29382888
Mol Pharmacol. 2006 Dec;70(6):1984-91
pubmed: 16959943
Cephalalgia. 2020 Aug;40(9):924-934
pubmed: 32223300
Cephalalgia. 2009 Apr;29(4):408-17
pubmed: 19055511
JAMA. 2019 Nov 19;322(19):1887-1898
pubmed: 31742631
Cephalalgia. 2019 Mar;39(3):354-365
pubmed: 28971699
Cephalalgia. 2021 Mar;41(3):305-317
pubmed: 32985222
J Neurosci. 2017 Nov 1;37(44):10587-10596
pubmed: 28972120
J Pain. 2013 Nov;14(11):1289-303
pubmed: 23958278
J Pharmacol Exp Ther. 2020 Jan 28;:
pubmed: 31992609
J Neurosci. 2010 Jun 30;30(26):8807-14
pubmed: 20592202
Pain Rep. 2017 Dec 05;3(1):e632
pubmed: 29430561
Sci Rep. 2020 Jul 10;10(1):11408
pubmed: 32651400
Cephalalgia. 2019 Dec;39(14):1762-1775
pubmed: 31550910
J Neurosci. 2017 Jul 26;37(30):7149-7163
pubmed: 28642283
Cephalalgia. 2021 Jan;41(1):17-32
pubmed: 33200944
J Mol Neurosci. 2020 Jun;70(6):930-944
pubmed: 32086679
Cephalalgia. 2018 Jul;38(8):1442-1454
pubmed: 29848108
Cephalalgia. 2017 May;37(6):560-570
pubmed: 27206958
Br J Pharmacol. 2004 Aug;142(7):1171-81
pubmed: 15237097
Cephalalgia. 2021 Apr;41(5):499-514
pubmed: 33626922
Ann Clin Transl Neurol. 2015 Jun;2(6):595-608
pubmed: 26125036
Cephalalgia. 2018 Mar;38(3):437-451
pubmed: 28165287
J Headache Pain. 2013 Nov 20;14:93
pubmed: 24256609
Br J Pharmacol. 2018 Jan;175(1):3-17
pubmed: 29059473
J Neurophysiol. 1993 May;69(5):1621-31
pubmed: 8389833
Neurobiol Dis. 2001 Feb;8(1):1-10
pubmed: 11162235
N Engl J Med. 2017 Nov 30;377(22):2113-2122
pubmed: 29171818
Ann Neurol. 2011 May;69(5):855-65
pubmed: 21416489
Lancet. 2019 Aug 31;394(10200):737-745
pubmed: 31311674
Trends Neurosci. 2003 Dec;26(12):696-705
pubmed: 14624855
Cephalalgia. 2014 Feb;34(2):136-47
pubmed: 24000375
Ann Neurol. 2013 Aug;74(2):257-65
pubmed: 23686557
ACS Pharmacol Transl Sci. 2020 Feb 26;3(2):296-304
pubmed: 32296769
J Headache Pain. 2019 Nov 12;20(1):105
pubmed: 31718551
Lancet Neurol. 2020 Sep;19(9):727-737
pubmed: 32822633
Pain. 2021 Sep 1;162(9):2418-2427
pubmed: 34448754
J Headache Pain. 2019 Apr 30;20(1):44
pubmed: 31039731
Cephalalgia. 2018 May;38(6):1026-1037
pubmed: 29471679
Cephalalgia. 2021 Mar;41(3):329-339
pubmed: 33059476
Front Pharmacol. 2020 Aug 20;11:1240
pubmed: 32973499
Cephalalgia. 2019 Dec;39(14):1827-1837
pubmed: 31288556